ProAlgaZyme Novel Algae Infusion: Applications in Immunodeficiency

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effects in HIV patients of supplementation (4-20 fl. oz. daily) with ProAlgaZyme, a novel fermentation product of a freshwater algae ecosystem, on markers of immune status, dyslipidemia, inflammation and oxidative stress alone or in combination with HAART (highly-active antiretroviral therapy).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Health Enhancement Products, Inc.
• Collaborator: University of Yaounde

Criteria

Inclusion Criteria:

• Diagnosed as HIV +ve or HIV/HBV +ve

• Either/or:

• had not taken antiretroviral drugs before (pre-HAART patients)

• were treated with triple drug therapy for at least 3-6 months

Exclusion Criteria:

• Obese

• Taking any cholesterol-lowering medications 30 days prior to the start of enrollment and during the course of the study.

• Enrolled in another clinical study in the past 6 months.